Skip to main
XGN
XGN logo

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc. has demonstrated a strong revenue growth trajectory, with a reported year-over-year increase of 14.2%, driven primarily by its AVISE CTD product line, which has seen consistent volume growth and a rising average selling price (ASP) currently at $428. The company has also achieved a gross margin expansion of 30 basis points year-over-year, reaching 60.4%, indicating improved operational efficiency. Furthermore, Exagen's strategic focus on optimizing its product offerings and enhancing commercial reimbursement strategies suggests a robust potential for continued revenue growth, with projections indicating a 20.5% revenue increase for FY25 and 14.8% for FY26.

Bears say

Exagen Inc. is facing a challenging financial outlook as its gross margin decreased by approximately 70 basis points to 58.9%, primarily due to strategic investments ahead of a new biomarker launch and projected volume increases. Despite a top-line revenue of $17.2 million in Q2 2025, the company reported a GAAP EPS loss of $0.21, missing consensus expectations, alongside a downward revision of its 2025 revenue estimate to $66.0 million, driven by subdued expectations for the utilization of its AVISE CTD test. Furthermore, Exagen has not achieved profitability and does not anticipate being profitable in 2025, highlighting a reliance on external capital which might not be available under favorable terms, compounded by potential pressures on reimbursement rates for diagnostic tests.

Exagen Inc (XGN) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.